MYOC-Specific iRNA Compositions for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary open angle glaucoma, are inadequate in addressing the elevated eye pressure caused by MYOC protein misfolding, which leads to optic nerve damage and vision loss.
Innovation Solution
The use of MYOC-specific iRNA compositions to inhibit the expression of MYOC by targeting and cleaving MYOC mRNA transcripts, thereby reducing MYOC protein levels in ocular tissues, which in turn decreases intraocular pressure and slows disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for glaucoma are used, then existing therapy options are available, but they are inadequate in addressing elevated eye pressure caused by MYOC protein misfolding
Solution Approach 1:
The patent introduces iRNA as an intermediary molecule that mediates between the treatment goal (reducing MYOC protein) and the cellular machinery (RISC complex). The iRNA specifically binds to MYOC mRNA and guides the RISC complex to cleave it, providing a targeted mechanism that current glaucoma treatments lack. This intermediary approach enables selective inhibition of MYOC expression without affecting other pathways.
Solution Approach 2:
The patent replaces conventional mechanical or chemical treatment approaches (eye drops, surgery) with a molecular-level mechanism (RNA interference). Instead of applying external force or chemical pressure to reduce intraocular pressure, the invention uses biochemical specificity of nucleic acid base pairing to target and silence the MYOC gene at the mRNA level, fundamentally substituting the treatment mechanism.
2Reliability
If MYOC protein levels are reduced through iRNA, then intraocular pressure decreases and disease progression slows, but the complexity of the treatment mechanism increases
Solution Approach 1:
The iRNA molecule is designed to be self-directed, containing within its sequence the information needed to find and bind its target MYOC mRNA through complementary base pairing. The RISC complex uses the iRNA's inherent sequence specificity to automatically locate and cleave the correct mRNA without requiring external guidance or complex delivery systems, enabling the treatment to be self-directed at the molecular level.
3Quantity of substance
If MYOC-specific iRNA is used to inhibit MYOC expression, then MYOC protein levels are reduced by 10-95%, but specificity requirements for the iRNA sequence increase
Solution Approach 1:
The patent applies local quality by designing the iRNA to have high complementarity (0-3 mismatches) only at the critical binding region that contacts MYOC mRNA, while other regions can have more flexibility. This localized precision ensures specific targeting of MYOC without requiring perfect complementarity throughout the entire iRNA sequence, making the treatment effective while managing sequence design complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces MYOC protein levels in ocular tissues by 10-95%, effectively lowering intraocular pressure and ameliorating symptoms of glaucoma, such as optic nerve damage and vision loss, providing a potential new therapeutic approach for glaucoma treatment.
Implementation Method 1
The present disclosure describes methods and iRNA compositions for modulating the expression of MYOC... effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of MYOC
Implementation Method 2
the antisense strand having a region that is substantially complementary to at least part of an mRNA transcript of MYOC
Data Source
AI summary
The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting MYOC, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of MYOC.